Concepedia

Publication | Closed Access

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

DOI

422

Citations

19

References

2013

Year

Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard Kefford, Jean‐Jacques Grob,
Journal of Clinical Oncology

Abstract

Dabrafenib was well tolerated and clinically active in patients with BRAF(V600E/K) mut(+) MM. cfDNA may be a useful prognostic and response marker in future studies.

References

YearCitations

Page 1